Ascenta Capital
Venture capital
RollingLast verified 10 Nov 2026
Ascenta Capital is a venture capital firm investing $15–30M in biotech companies advancing clinical drug development through Phase 1 and 2 as well as multi-medicine platforms.
1 deal in the last 24 months, latest 12 Jan 2026. Derived from its deals in the news.
Key facts
- Stages
- Series C+
- Sectors
- Biotech & pharma
- Ticket
- €15M–€30M
- Eligible countries
- Not stated
- Timing
- Rolling applications
- Focus
- Phase 1 and 2 clinical development; multi-medicine platforms; biopharma
- How to apply
- Apply route unknown
Recent deals
| Company | Round | Sectors | Amount | Role | Announced |
|---|---|---|---|---|---|
| Tubulis | Series C+ | Biotech & pharma | €400M | lead | 12 Jan 2026 |
Evidence
Short excerpts from the sources, in their original language, that back the facts above.
- Kind
Ascenta Capital, Biotech Venture Capital & Drug Development
https://www.ascentacap.com/ - Sectors
Biotech Investments
https://www.ascentacap.com/ - Ticket
$15-30 Million
https://www.ascentacap.com/ - Ticket
$15-30 Million
https://www.ascentacap.com/
Status history
- 6 Nov 2026: Rolling (first extraction)
Is something out of date?
Suggest an editTakes 10 seconds
Something else wrong? Report an error.
Work at Ascenta Capital? Claim this profile to confirm what you invest in.